Two decades of commitment to malaria vaccine development: GlaxoSmithKline biologicals

被引：23

作者：

Ballou, W. Ripley ^{[1
]}

Cahill, Conor P. ^{[1
]}

机构：

[1] GlaxoSmithKline Biol, Global Clin Res & Dev, B-1330 Rixensart, Belgium

来源：

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2007年 / 77卷 / 06期

关键词：

D O I：

10.4269/ajtmh.2007.77.289

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];

摘要：

GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily con the company's global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and cornmercialization. Through GSK's pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.

引用

页码：289 / 295

页数：7

共 69 条

[1]

ORAL SALMONELLA - MALARIA CIRCUMSPOROZOITE RECOMBINANTS INDUCE SPECIFIC CD8+ CYTOTOXIC T-CELLS [J].

AGGARWAL, A ;

KUMAR, S ;

JAFFE, R ;

HONE, D ;

GROSS, M ;

SADOFF, J .

JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) :1083-1090

[2]

Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific [J].

Alloueche, A ;

Milligan, P ;

Conway, DJ ;

Pinder, M ;

Bojang, K ;

Doherty, T ;

Tornieporth, N ;

Cohen, J ;

Greenwood, BM .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 68 (01) :97-101

[3]

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].

Alonso, PL ;

Sacarlal, J ;

Aponte, JJ ;

Leach, A ;

Macete, E ;

Aide, P ;

Sigauque, B ;

Milman, J ;

Mandomando, I ;

Bassat, Q ;

Guinovart, C ;

Espasa, M ;

Corachan, S ;

Lievens, M ;

Navia, MM ;

Dubois, MC ;

Menendez, C ;

Dubovsky, F ;

Cohen, J ;

Thompson, R ;

Ballou, WR .

LANCET, 2005, 366 (9502) :2012-2018

[4]

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].

Alonso, PL ;

Sacarlal, J ;

Aponte, JJ ;

Leach, A ;

Macete, E ;

Milman, J ;

Mandomando, I ;

Spiessens, B ;

Guinovart, C ;

Espasa, M ;

Bassat, Q ;

Aide, P ;

Ofori-Anyinam, O ;

Navia, MM ;

Corachan, S ;

Ceuppens, M ;

Dubois, MC ;

Demoitié, MA ;

Dubovsky, F ;

Menéndez, C ;

Tornieporth, N ;

Ballou, WR ;

Thompson, R ;

Cohen, J .

LANCET, 2004, 364 (9443) :1411-1420

[5]

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine [J].

Angov, E ;

Aufiero, BM ;

Turgeon, AM ;

Van Handenhove, M ;

Ockenhouse, CF ;

Kester, KE ;

Walsh, DS ;

McBride, JS ;

Dubois, MC ;

Cohen, J ;

Haynes, JD ;

Eckels, KH ;

Heppner, DG ;

Ballou, WR ;

Diggs, CL ;

Lyon, JA .

MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2003, 128 (02) :195-204

[6]

IMMUNIZATION OF OWL MONKEYS WITH A RECOMBINANT PROTEIN CONTAINING REPEATED EPITOPES OF A PLASMODIUM-FALCIPARUM GLYCOPHORIN-BINDING PROTEIN [J].

ARONSON, NE ;

SILVERMAN, C ;

WASSERMAN, GF ;

KOCHAN, J ;

HALL, BT ;

ESSER, K ;

YOUNG, JE ;

CHULAY, JD .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 45 (05) :548-559

[7]

IMMUNOGENICITY OF SYNTHETIC PEPTIDES FROM CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-FALCIPARUM [J].

BALLOU, WR ;

ROTHBARD, J ;

WIRTZ, RA ;

GORDON, DM ;

WILLIAMS, JS ;

GORE, RW ;

SCHNEIDER, I ;

HOLLINGDALE, MR ;

BEAUDOIN, RL ;

MALOY, WL ;

MILLER, LH ;

HOCKMEYER, WT .

SCIENCE, 1985, 228 (4702) :996-999

[8]

BALLOU WR, 1987, LANCET, V1, P1277

[9]

Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].

Bojang, KA ;

Milligan, PJM ;

Pinder, M ;

Vigneron, L ;

Alloueche, A ;

Kester, KE ;

Ballou, WR ;

Conway, DJ ;

Reece, WHH ;

Gothard, P ;

Yamuah, L ;

Delchambre, M ;

Voss, G ;

Greenwood, BM ;

Hill, A ;

McAdam, KPWJ ;

Tornieporth, N ;

Cohen, JD ;

Doherty, T .

LANCET, 2001, 358 (9297) :1927-1934

[10]

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children [J].

Bojang, KA ;

Olodude, F ;

Pinder, M ;

Ofori-Anyinam, O ;

Vigneron, L ;

Fitzpatrick, S ;

Njie, F ;

Kassanga, A ;

Leach, A ;

Milman, J ;

Rabinovich, R ;

McAdam, KPWJ ;

Kester, KE ;

Heppner, DG ;

Cohen, JD ;

Tornieporth, N ;

Milligan, PJM .

VACCINE, 2005, 23 (32) :4148-4157

← 1 2 3 4 5 6 7 →